The information contained in these regimens is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. The treatment regimen to be used should take into account factors such as histology, molecular pathology, age, performance status, co-morbidities and the patient’s preference. Each treatment regimen has advantages and disadvantages, and there may be more than one good option. In addition, treatment choices can change over time as more evidence becomes available. Use of these documents is the responsibly of the prescribing clinician and is subject to the HSE.ie terms of use.
Please email any comments or feedback on these regimens to oncologydrugs@cancercontrol.ie.
For information on open clinical trials please refer to the Cancer Trials Ireland website here and also to basket trials here.
Regimen Name |
Indication |
Denosumab 120mg Therapy
Regimen
|
00741a
For the prevention of skeletal related events in adult patients with malignancies involving bone.
|
Zoledronic Acid Therapy-28 days
Regimen
|
00723a
Prevention of skeletal related events in malignancies involving bone metastases
|
Zoledronic Acid Therapy-3 monthly
Regimen
|
00724a
Prevention of skeletal related events in malignancies involving bone metastases
|
Zoledronic Acid Therapy-6 monthly
Regimen
|
00725a
Prevention of skeletal related events in malignancies involving bone metastases
|